Sage Therapeutics, Inc. (SAGE)

Market Cap	841.49M
Revenue (ttm)	86.46M
Net Income (ttm)	-541.49M
Shares Out	60.11M
EPS (ttm)	-9.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,306,912
Open	13.52
Previous Close	12.95
Day's Range	13.45 - 14.52
52-Week Range	10.92 - 59.99
Beta	0.85
Analysts	Hold
Price Target	21.47 (+53.36%)
Earnings Date	Apr 25, 2024

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2014
• Employees: 487
• Stock Exchange: NASDAQ
• Ticker Symbol: SAGE

Financial Performance

In 2023, SAGE's revenue was $86.46 million, an increase of 1024.84% compared to the previous year's $7.69 million. Losses were -$541.49 million, 1.63% more than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for SAGE stock is "Hold." The 12-month stock price forecast is $21.47, which is an increase of 53.36% from the latest price.

Price Target

$21.47

(53.36% upside)

Analyst Consensus: Hold